5 recruiting, 2 active not recruiting, 2 completed, 2 terminated. 14 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Recruiting 5, Active not recruiting 2, Completed 2, Terminated 2, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 3 | Not yet recruiting 1, Terminated 1, Withdrawn 1 |
Follow Urothelial Carcinoma Bladder: new trials by email Literature Review of Urothelial Carcinoma Bladder trials Research Report on Urothelial Carcinoma Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. Gemcitabine + BCG, BCG (TICE strain) - NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Queen's University | 31 | 2025-08-01 | 2025-07-17 |
| Intervention of Bladder Cancer by CAR-T 4SCAR-PSMA, 4SCAR-FRa - Bladder Cancer, Urothelial Carcinoma Bladder | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2025-08-01 | 2026-10-30 |
| Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy - Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter | Phase 2 | Recruiting | Nagoya University | 43 | 2025-05-01 | 2025-08-14 |
| 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma 9MW2821, Toripalimab (JS001 ) - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 60 | 2025-01-17 | 2025-03-21 |
| Renal Retention in High Grade Upper Tract Urothelial Cancer Enfortumab vedotin, Pembrolizumab - High Grade Urothelial Carcinoma, Bladder Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 20 | 2024-11-25 | 2026-01-08 |
| Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy Reproductive organ sparing radical cystectomy, Radical cystectomy - Urothelial Carcinoma Bladder | Phase 2 | Recruiting | University of Florida | 127 | 2024-08-30 | 2026-09-09 |
| Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Milademetan, Atezolizumab - Advanced Solid Tumor, CDKN2A | Phase 1 / Phase 2 | Withdrawn | Rain Oncology Inc | 2023-05-19 | 2023-10-19 | |
| Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer Atezolizumab, Carboplatin, Cisplatin - Small Cell Neuroendocrine Carcinoma of Bladder, Bladder Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 63 | 2022-06-27 | 2026-06-25 |
| Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer Tislelizumab, Gemcitabine, Cisplatin - Urothelial Carcinoma Bladder, PD-1 Inhibitor | Phase 2 | Unknown | RenJi Hospital | 20 | 2022-06-01 | 2022-08-18 |
| IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC IO102-IO103 in combination with pembrolizumab - Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | IO Biotech | 63 | 2022-04-11 | 2026-04-08 |
| Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer Sasanlimab, Stereotactic Body Radiation Therapy, Radical Cystectomy + pelvic lymph node dissection + urinary diversion - Urothelial Carcinoma Bladder | Phase 2 | Active not recruiting | The Methodist Hospital Research Institute | 33 | 2022-02-15 | 2025-10-24 |
| Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer Gemcitabine, Docetaxel - Urothelial Carcinoma Bladder, Bladder Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 27 | 2020-07-29 | 2025-11-17 |
| A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer UGN-102 - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Completed | UroGen Pharma Ltd. | 63 | 2018-10-15 | 2022-09-16 |
| A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma Sitravatinib, Nivolumab, Pembrolizumab - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 2 | Terminated | Mirati Therapeutics Inc. | 260 | 2018-09-11 | 2023-08-24 |
Urinary Bladder Neoplasms (7) · Carcinoma, Transitional Cell (5) · Non-Muscle Invasive Bladder Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Melanoma (1) · Mesothelioma (1) · Neoplasms (1) · Stomach Neoplasms (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1) · Urinary Bladder Diseases (1) · Urologic Diseases (1) · Urologic Neoplasms (1)
Neoplasms (12) · Neoplasms by Site (10) · Carcinoma (9) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Male Urogenital Diseases (9) · Neoplasms by Histologic Type (9) · Neoplasms, Glandular and Epithelial (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Urologic Diseases (8) · Urologic Neoplasms (8) · Urinary Bladder Diseases (7) · Carcinoma, Squamous Cell (2) · Head and Neck Neoplasms (2)
Cisplatin (3) · Cystectomy (3) · Gemcitabine (3) · pembrolizumab (3) · atezolizumab (2) · enfortumab vedotin (2) · BCG Vaccine (1) · Carboplatin (1) · Docetaxel (1) · Etoposide (1) · Immune Checkpoint Inhibitors (1) · Mitomycin (1) · Nivolumab (1) · Podophyllotoxin (1) · Radiosurgery (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · IO Biotech (1) · Mabwell (Shanghai) Bioscience Co., Ltd. (1) · Mirati Therapeutics Inc. (1) · Nagoya University (1) · Queen's University (1) · Rain Oncology Inc (1) · RenJi Hospital (1) · Shenzhen Geno-Immune Medical Institute (1) · The Methodist Hospital Research Institute (1) · University of Florida (1) · UroGen Pharma Ltd. (1)
United States (8) · China (3) · Canada (1) · Israel (1) · Japan (1) · Spain (1) · United Kingdom (1)
Jean Hoffman-Censits, MD (2) · Elyse Seltzer, MD (1) · Hirak Der-Torossian, MD (1) · Jonathan W Riess, MD, MSc (1) · Lung-Ji Chang, PhD (1) · Max Kates, MD (1) · Raj Satkunasivam, MD (1) · Syusuke Akamatsu (1) · Tarik Benidir, MD (1) · Wei Xue, PhD (1)
PMID 34433303, PMID 35640276, PMID 35703113, PMID 38849479, PMID 41074972